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8INTRODUCTION
Von Hippel-Lindau disease (VHL) is a rare dominantly inherited cancer syndrome
predisposing to multiple hemangioblastomas (HB) of the CNS and retina, renal cell
carcinomas (RCC), pancreatic carcinoma, pheochromocytomas, and visceral cysts. VHL is
caused by a defect in the VHL tumor suppressor gene in chromosome 3p25-p26. VHL
clearly reduces the length of life, as the mean age at death is 40 to 50 years. Due to
advances in microsurgery, RCC has exceeded HBs of the CNS as the leading cause of
death in VHL.
The HB is a highly vascular, benign and well-circumscribed, slowly growing solid
or cystic neoplasm of the CNS and retina. (1) HB of the CNS is regarded to be sporadic in
60-90% of the cases and then it is typically a single, cystic lesion of the cerebellum,
presenting at the average age of somewhat over 40 years. In VHL, HBs of the CNS appear
10 years earlier. Microsurgery is the treatment of choice aided, if necessary, by
preoperative embolization to reduce intraoperative bleeding. Radiosurgery offers a non-
invasive means to treat HBs in eloquent brain areas. (2) HB of the retina originates from
the inner, mid-peripheral retina, and is histologically identical to HB of the CNS. Retinal
HB is the first manifestation in about half of the VHL patients at the mean age of 25 years,
and is usually bilateral and multifocal, or becomes so over the years. There are sporadic
retinal HBs without VHL, but their prevalence has remained undefined. Retinal HBs, even
when small and asymptomatic, should be treated with laser or cryocoagulation to prevent
loss of vision.
There is increased morbidity related to repeated microsurgery and radiosurgery of
HBs of the CNS, as well as coagulation of retinal HBs. Therefore, it is justifiable to seek
other approaches to treat multiple HBs. Antiangiogenic tumor therapy is targeted to small
foci of migrating and proliferating endothelial cells in capillaries at sites of angiogenesis, in
an attempt to inhibit tumor growth. Interferon-alpha (IFNα) is a well-tolerated drug with
immunomodulatory, antiproliferative and antiangiogenic activities. It has an established
role in certain types of cancer, and it is especially effective in life-threatening hemangiomas
of the liver and facial areas in children.
Long-term follow-up data on patients with HBs of the CNS and/or retina, treated
with population responsibility and distinction of VHL, have remained scarce. The effect of
radiosurgery in HBs of the CNS remains undetermined. There are no published data on the
9effect of IFNα therapy in HBs of the CNS and retina. The aims of this thesis were to study
the VHL prevalence and long-term prognosis of patients with HBs of the CNS and retina,
the results of gamma knife radiosurgery in HBs of the CNS, and the impact of 12-month
IFNα2a therapy in HBs of the CNS and retina.
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REVIEW OF THE LITERATURE
    1. Hemangioblastomas (HB)
Hemangioblastomas of the CNS
The HB is a highly vascular, benign and well-circumscribed, slowly growing solid
or cystic neoplasm of the CNS and retina composed of stromal cells, endothelial cells,
pericytes, and mast cells14,17. The origin of the stromal cells, believed to be the true
neoplastic cells of HB tissue, is still undefined17. HB may cause polycytemia by secreting
erythropoietin from stromal or mast cells16,73,113,119. HB of the CNS is one of the
manifestations of von Hippel-Lindau disease (VHL) (see below), but is regarded to be
sporadic in 60-90% of the cases, and then it is typically a single, cystic lesion of the
cerebellum96, brain stem or upper cervical medulla, presenting at the average age of
somewhat over 40 years12,108,117,139. Supratentorial HBs are rare 138,150. HBs have
also been described to occur rarely in spinal nerve roots60,167, peripheral nerves13,24,
and the optic nerve8,83,145. Microsurgery is the treatment of choice in HBs of the
CNS36,138,163 aided, if necessary, by preoperative embolization to reduce intraoperative
bleeding49,156,164.
Hemangioblastomas of the retina
The retina consists of 10 layers and contains blood vessels in its inner layers38,43.
After photoreception by the rods and cones, the bipolar cells in the inner nuclear layer
transmit their signals to the ganglion cells, the axons of which form the optic nerve. The
central area of the retina (macula lutea) has the highest visual acuity in its cone-rich center,
i.e. the fovea (diameter 150 m-6). HB of the retina originates from the inner, mid-peripheral
retina, and is histologically identical to HB of the CNS68. Mature HBs resembling ‘sugar-
powdered’ raspberries and the adjoining dilated, tortuous arterioles and venules (feeder
vessels) are distinctive enough to permit visual diagnosis after pupillary dilatation with
indirect ophthalmoscopy, Goldmann 3-mirror contact lens or non-contact lens fundus
examination123,174. Incipient HBs are small, reddish or grayish dots, without abnormal
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adjoining vessels151. In retinal HBs, fluorescein angiography (FA) shows an arteriovenous
shunt with leakage of dye due to incompetent capillary walls. FA may help to detect small
HBs not yet accompanied by enlarged vessels155, but incipient lesions may fail to fill with
fluorescein. For this reason, and its possible side-effects, FA is not recommended as a
screening tool123,151. In differential diagnosis, HBs of the optic disc10,76 may resemble
papillitis, papilledema, chorioiditis, or chorioidal hemangioma76,155,177. Cavernous
hemangiomas of the retina appear as grape-like clusters of dilated vascular sacs without
pronounced alteration in the adjacent arterioles and venules7. Coats’ disease with dilated,
tortuous and leaking retinal venules may cause exudative detachment of the retina in
children and teenagers155.
HBs of the retina can be asymptomatic for years, and may even regress
spontaneously172. Usually, however, symptoms such as flashing and floaters occur and
there is progressive visual impairment due to leakage from the incompetent capillary walls
of HBs. This leads to secondary changes in the vitreous and retina such as premature
posterior vitreous detachment, retinal break, vitreous hemorrhage, lipid exudates and
edema in the macula, or preretinal fibrosis123,174. In advanced cases, total retinal
detachment may occur either due to accumulation of fluid between the photoreceptor layer
and the retinal pigment epithelium caused by excessive leakage from large HBs, vitreous
traction caused by vitreous strands and epiretinal membranes and/or retinal breaks123.
Early lesions are easy to eradicate, and they carry the lowest risk of complications.
Therefore, retinal HBs should be treated even when small and asymptomatic with laser or
cryocoagulation for a better prognosis of vision174.
     2. von Hippel-Lindau disease (VHL)
Definition
VHL is a rare (1/36 000 alive births) dominantly inherited cancer syndrome caused
by a tumor suppressor gene defect predisposing to multiple hemangioblastomas (HB) of
the CNS and retina, renal cell carcinomas (RCC), pheochromocytomas, pancreatic
carcinoma, and cysts in the kidneys, liver, and pancreas31,52,53,67,97,104,118,138,176.
Also, several other less common lesions have been described118,138, such as epididymal
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cystadenomas2, and endolymphatic sac tumors82,109. Diagnosis of VHL is based on VHL
gene mutation analysis94,161 and/or clinical manifestations over long-term follow-
up31,108,111,114. A patient with HB of the CNS or retina is classified as having VHL if
the patient has a germline mutation, family history of VHL, or other VHL-related
neoplasms (HBs of the CNS or retina, RCC, pheochromocytoma).
Historical aspects
In 1911, Eugen von Hippel, a German ophthalmologist, defined retinal HBs as a
cystic capillary angiomatosis of congenital origin176. In 1926-1927, Arvid Lindau, a
Swedish pathologist, disclosed the relationship between HBs of the CNS and retina and
visceral lesions97,98. In 1992, Grossniklaus et al. 68 showed that HBs of the retina are
histologically identical to their counterparts in the CNS. In 1993, Latif et al.93 identified
the VHL tumor suppressor gene, which, together with modern imaging of the CNS and
abdomen, have improved the diagnosis of VHL also in asymptomatic carriers.
Genetics of VHL
VHL is caused by a defect in the VHL tumor suppressor gene in chromosome
3p25-p2694,141. The function of the VHL gene is not fully understood41,144, but loss of
the gene product (pVHL) function44,45,75,84,126 in normoxic conditions may lead to an
inappropriate expression of hypoxia-inducible proteins such as the vascular endothelial
growth factor (VEGF)55,80,133, which may account for the hypervascular nature of
VHL-associated neoplasms64,70,162. VHL is an autosomal dominant trait with a high
penetrance, as almost 100 % of the carriers of a VHL gene defect will develop clinical
manifestations by the age of 60 years108. Their children have a 50% risk of getting the
disease104,108,118. Half of the VHL cases are familial and half are caused by new
mutations, estimated to occur at 4.4x106 gametes per generation104. Several mutations
have been described, and a VHL gene mutation database has been established11.
Mutations are heterogeneous in type and position, and VHL shows intra- and interfamilial
differences in phenotype37,81,138,142,171,178. Direct sequencing of the VHL gene has
an expected detection rate of 60-70% of the VHL gene mutations but it misses
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deletions161,178. Quantitative Southern blotting can be used to detect deletions of the
entire VHL gene, Southern blotting to detect partial deletions, and fluorescence in situ
hybridization (FISH) to confirm deletions of the entire VHL gene161. By combining these
techniques, virtually all mutations can be detected in definite VHL families161.
There is some genotype-phenotype correlation: germline mutations predicted to
inactivate the VHL protein are associated with RCC and HBs of the CNS without
pheochromocytoma (Type 1), and germline mutations predicted to produce full-length
VHL proteins are associated with pheochromocytoma and other VHL manifestations
(Type 2)25,37,106,161,178. However, it is still not possible to predict reliably the severity
and spectrum of VHL manifestations based on any single VHL gene defect.
Manifestations of VHL
Multiple HBs of the CNS are a typical manifestation of VHL. HBs of the CNS
occur about 10 years earlier than their sporadic counterparts, at the average age of about
30 years12,108,117,139. Of the patients with HBs of the CNS, 10-40% have
VHL12,107,117,139. In VHL, as compared to sporadic cases, HBs of the CNS are more
often located in the brainstem and spinal cord138. Analogous to cerebellar HBs that often
produce cysts, spinal cord HBs may induce syringomyelia149. When symptomatic, HBs of
the CNS cause disruption of neurological functions, or symptoms due to raised intracranial
pressure, often caused by the adjoining cyst. Magnetic resonance imaging (MRI) enables
the detection of even incipient asymptomatic HBs of the CNS in VHL.
Retinal HB is the first manifestation in about half of the VHL patients118, and is
usually bilateral and multifocal, or becomes so over the years105,118. The mean age at
presentation is 25 years118 118,174 and the estimated cumulative probability to develop
retinal HBs exceeds 70% by the age of 60 years108. There is no general influence of
germline mutation on the severity of retinal HBs170.
VHL occurs in only 2% of RCC patients, whereas in VHL patients RCC develops
in up to 45% of the patients62,63,121. Compared to sporadic RCC, in VHL patients RCC
is characterized by appearing 25 years earlier (i.e. at the average age of 35 years), an
association with renal cysts, multifocal and bilateral tumors, and low grade
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histology72,121,135. The incidence of metastatic disease for VHL patients with RCC has
been reported to be 20%114. The distribution of metastases is similar to that of sporadic
cases of RCC including liver, lung and bones. Abdominal computed tomography (CT) with
contrast, using 5 mm contiguous sections represents preferable radiographic assessment of
the kidney32,65. CT helps in differentiating simple cysts (smooth borders and a
homogeneous attenuation similar to water) and complex cysts (mostly cystic but
containing some solid elements) from solid masses (attenuation higher than water and
enhanced with contrast)65. Renal ultrasonography (US) is a useful screening method, but
does not offer comparable anatomic detail65. For patients with advanced renal
insufficiency or contrast allergy, MRI before and after gadolinium yields equivalent results
to CT. Renal arteriography is important for surgical planning when a partial nephrectomy
is anticipated65. Earlier, nephrectomies were often performed, but lately nephron-sparing
surgery (lesionectomy or partial nephrectomy), whenever possible, has been recommended
as primary treatment65. The prognosis of RCC is better in VHL patients than in sporadic
ones, and metastases are claimed to appear in VHL only after the primary tumor exceeds 7
cm in diameter121. It has been proposed that single tumors should be excised already
when their diameter is 2-3 cm100.
Pheochromocytomas are catecholamine-producing tumors of the adrenal
medulla5,6,27,28,48 occurring in 20-35% of VHL patients at the median age of 30
years118,138. About 20% of all pheochromocytomas are related to VHL116. In VHL,
these tumors tend to be bilateral and multiple, but they are rarely malignant116,138.
Pheochromocytomas can be located within or outside the adrenals116. Presenting
symptoms are palpitations, headache, sweating attacks and hypertension. The diagnosis is
based on imaging of the adrenals by US, CT or MRI, and supported by measurement of
plasma and urine catecholamines. In extra adrenal lesions, scintigraphy with 123I or 131I-
labeled metaiodobezylguanetidine is usually diagnostic116,118. Symptomatic tumors
should be enucleated rather than treated by adrenalectomy118,122.
Pancreatic adenocarcinoma and malignant islet cell tumors occur in VHL92
108,118,138
. Therefore, VHL patients should be followed regularly with abdominal CT or
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MRI scans to detect asymptomatic lesions so that they could be operated before the
appearance of metastases.
VHL predisposes to cysts in the kidneys, pancreas and liver29,31,32,118. These
cysts tend to be multiple, e.g. in the kidneys bilateral and slowly growing32, and they
require follow-up because of the possible adjoining malignancy135. Renal cysts are usually
asymptomatic and do not require treatment as such. In polycystic kidney disease15,
another autosomal dominant disease, the number of cysts usually exceeds that detected in
VHL, and there are no adjoining malignancies. VHL patients with large pancreatic cysts
may have mild discomfort, but bile duct obstruction, pancreatitis, and hormonal
insufficiency requiring surgical intervention are rarely reported9,54.
Epididymal cystadenomas have been observed in 3% of VHL patients30,118, and
in bilateral cases they may impair fertility. After manual examination or US, they may be
excised, but usually this does not improve fertility40,118,175. Endolymphatic sac tumors
(ELST) are destructive neoplasms located in the posterior wall of the petrous bone in the
region of the vestibular aqueduct82,109. The usual symptoms are tinnitus, hearing loss and
vertigo. If left untreated, ELSTs usually progress and cause total deafness109. Complete
surgical excision, if possible, is recommended and may preserve hearing109.
Prognosis of VHL
The mean age at death in VHL is 40 to 50 years115. RCC has exceeded HBs of
the CNS as the primary cause of death (50 and 30%, respectively) due to advances in the
microsurgery of HBs of the CNS105. About 5% of VHL patients die from endogenous
catecholamine intoxication caused by pheochromocytomas116, and less than 5% from
pancreatic carcinoma115.
    3. Problems of treatment in VHL
Hemangioblastomas of the CNS
In VHL, microsurgical treatment of multiple HBs often fails in the long run.
Removed tumors tend to recur39 and new ones develop; some are symptomatic and others
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incidental. It is often difficult to decide which tumors should be removed, and operative
risks should be weighed against the natural course. Furthermore, in VHL, more often than
in sporadic cases, HBs are located in the brainstem and spinal cord138 increasing the risk
of morbidity and mortality related to microsurgery of these lesions. The operative mortality
for a cerebellar cystic tumor is less than 2%, but it increases considerably for a large solid
lesion intrinsic to the caudal brainstem137. Stereotactic radiotherapy may offer a safer
means to treat HBs in eloquent brain areas, but overlapping fields in patients with multiple
HBs may pose a problem of radiation injury to the adjacent brain.
Hemangioblastomas of the retina
In VHL, the appearance of new and multiple HBs of the retina typically threaten
vision118,138,170,174. All retinal HBs, even small and asymptomatic, should be treated
with laser or cryocoagulation to prevent loss of vision174. However, in papillary or
macular HBs, coagulation may cause a central visual field defect, and treatment is not
advised until exudation develops123,174. The feeder vessels and exudates do not require
direct treatment, their presence is secondary to the HB, and the treatment of feeders may
cause hemorrhage123,155.
Laser coagulation often requires multiple sessions to scar the entire HB155,174. A
single session may be adequate if the HB is very small (0.5 DD; 1 DD ~ 1.5 mm)155,174.
The success of treatment can be determined about two months after treatment155,
attenuation of the feeders and absence of fluorescein leakage from the HB are suggestive
of a good result155. In the cryocoagulation of larger lesions, the cryoprobe is located
directly over the HB transsclerally in indirect ophthalmoscopy. An initial treatment
temperature of -50°C is recommended to decrease the risk of hemorrhage when the
temperature is lowered during the same session to the range of -60 to -80°C123,155.
Treatment at a temperature higher than -80°C avoids excessive uveitis and exudation. If
the HB shows little or no whitening during freezing, the thermal barrier of subretinal fluid
or exudate is too great for cryosurgery to be effective155. If freezing produces at least
partial whitening of the HB, the freezing should be repeated twice155. If the feeders have
not attenuated by two months after cryotherapy, the treatment should be repeated. At six
months after therapy, the HB should appear as a pigmented scar, the exudate surrounding
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the HB should have diminished or disappeared, the feeders should be atrophic, and the
macula dry155. Brachytherapy with episcleral ruthenium-106 plaques has also been used
to treat large (>2 DD) lesions89.
Late recurrences may develop mainly due to incomplete primary destruction of the
HB, but in VHL new tumors may be mistaken for recurrences4. Retinal detachment
without vitreous traction may be treated by scleral encircling procedures. Macular
preretinal fibrosis, vitreous hemorrhage or retinal detachment threatening the macula may
necessitate vitreoretinal surgery91,103,110 which has improved the prognosis of vision in
eyes with large HBs. Cataract and neovascular glaucoma following total retinal
detachment are late complications of the disease with a poor prognosis123. Enucleation
may become mandatory in the case of a blind and painful eye174.
Renal cell carcinoma (RCC)
VHL patients tend to develop multiple bilateral RCCs threatening renal function
and life115,118. The decision to proceed with nephron-sparing surgery or radical
nephrectomy depends on the extent of the disease65. Nephron-sparing surgery may be
effective for patients with localized RCC, but most will have local recurrences. There are
also patients in whom nephron-sparing surgery is not feasible and bilateral nephrectomy
has to be performed.
In a series of 65 VHL patients with RCC treated with radical nephrectomy or
nephron-sparing surgery, the RCC-specific survival rate at 5 and 10 years was 95 and
77%, respectively157. However, altogether 23% of the patients developed end-stage renal
failure157, and at this stage, management options include dialysis or renal transplantation.
In a multicenter series of 28 VHL patients with end stage RCC and renal
transplantation65,66, the average age at diagnosis of RCC was 31 years and at
transplantation 37 years. The mean duration of dialysis before transplantation was 28
months (range 2-84 months). Twenty-three patients (82%) were alive without evidence of
recurrent disease at a mean of 51 months after transplantation. The need for a surveillance
interval during dialysis, in order to prevent the early development of metastatic disease
after transplantation is important. According to a review of 56 patients in whom incidental
RCC had been removed at variable times before transplantation132, patients with low
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stage, asymptomatic RCC did not need a surveillance interval before transplantation.
However, patients with symptomatic higher stage RCC have a greater risk of recurrent
disease, and a surveillance interval of at least two years is recommended before
transplantation132. When a VHL patient is considered for renal transplantation, VHL
exclusion in living related donors is mandatory.
    4. Novel treatment methods
Stereotactic radiotherapy
Stereotactic radiotherapy (SR) is a non-invasive and well-tolerated means to shrink
or control well-delineated intracranial neoplasms and to occlude AVMs158,160. For single
session treatment (‘radiosurgery’) the targets should be small (< 30 mm) because of a
dose-volume-dependent risk of delayed radiation injury, but fractionation using a
relocatable head frame allows larger volumes. HB and hemangiopericytoma (HPC) are
highly vascular, sharply circumscribed solid tumors that dislocate rather than infiltrate the
adjacent brain. HPC is semi-malignant and possibly therefore its response is dramatic and
rather rapid: most of 11 meningeal HPCs in five patients treated with the gamma knife
(GK) shrank within 6 to 10 months after an average margin dose of 15 (range 12 - 18)
Grays (Gy)34. The only morbidity was a partial visual-field defect in one patient. AVMs,
highly vascular non-neoplastic congenital lesions of the brain, respond by slow obliteration
of the nidus within one to three years, suggesting that the vessel walls of AVMs are prone
to a specific mechanism of delayed radiation injury that finally occludes
them59,101,158,159. In a series of 227 AVMs101, treated in one session with the GK
with an average margin dose of 21 (range 12 - 27) Gy, the 2-year obliteration rate
according to volume was 100% (< 1 cm3), 85% (1-4 cm3) and 58% (> 4 cm3). Symptoms
attributable to radiation injury developed in 6% of the patients at a mean interval of 10
months. Radiosurgery (RS) seems to reduce the risk of rebleeding in cavernous
hemangiomas88, a congenital vascular malformation receiving less arterial supply than
AVMs,  but the overall role of RS vs. microsurgery in the treatment of these lesions
remains to be elucidated99,160.
HBs should be ideal targets for RS because they are usually small, rounded, well-
delineated and highly vascular, and in VHL patients they are often multiple117,118,138.
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They receive an intense arterial supply from the adjacent brain tissue, and one might expect
obliteration of these feeding vessels. In order to be superior to microsurgery, RS of HBs
should be safer in eloquent areas in terms of radiation injury, it should shrink the tumor or
at least stop its growth in the long run, and prevent expansion or formation of cysts. RS is
apparently superior in terms of hospital stay and immediate costs, but years of follow-up
and possible surgery later may result in a different total.
Antiangiogenic therapy
Angiogenesis is fundamental to reproduction, development and repair57.
Pathological angiogenesis with unabated blood vessel growth sustains progression of many
neoplastic and non-neoplastic diseases57. Antiangiogenic tumor therapy is targeted at
small foci of migrating and proliferating endothelial cells in capillaries at sites of
angiogenesis56,143, an attempt to inhibit tumor growth86,90,127,128.
Interferon-alpha (IFNα) with immunomodulatory, antiproliferative and
antiangiogenic activities, has an established role in cancer therapy71,154. In hairy cell
leukemia, patients treated with IFNα have a 89% survival rate at five years, in comparison
to 34% in patients without any therapy58. In life-threatening hemangiomas of the liver and
facial areas in children, the response to long-term IFNα treatment at a high dosage is often
favorable, as most lesions shrink markedly by 12 months when treated with 3x106
International Units (IU)/m2 daily51. In metastatic cutaneous melanomas and RCCs, better
response rates and prolonged survival are achieved with treatment regimens containing
IFNα as compared to regimens without it71.
In general, IFNα is well tolerated. Its side-effects are dose-dependent, usually
being transient acute mild flu-like symptoms after injections85,134. Subacute and chronic
adverse effects include fatigue, leukopenia, and less commonly, thrombocytopenia and
anemia85,134,165. Pulmonary and cardiac toxic effects have been encountered after weeks
or months of therapy173, but severe cardiomyopathy as well as fatal multiorgan failures
have been described within the first few days of therapy20,35,136. In long-term use and
with higher doses, neurotoxicity with gait disorders, dizziness, and memory problems have
been described42,173. Notably, patients affected by depression during long-term treatment
20
are at increased risk of becoming manic if IFNα treatment is withdrawn abruptly19. The
mechanism of IFNα-linked mood disorders is unknown.
In VHL, HBs of the CNS and retina could be ideal targets for systemic
antiangiogenic therapy because they are highly vascular, often multiple, and located in
eloquent brain areas with increased microsurgical and radiosurgical risks, and VEGF may
have a role in their pathogenesis64,70,162. There are no published data on the effect of
IFNα in the treatment or prevention of HBs of the CNS and retina.
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AIMS OF THE STUDY
This study was aimed to answer the following questions:
I HB of the CNS: VHL prevalence and long-term prognosis?
II HB of the retina: VHL prevalence and long-term prognosis of vision?
III HB of the CNS: impact of stereotactic radiosurgery?
IVAsymptomatic HBs of the CNS and retina: impact of 12-month treatment with
IFNα2a?
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PATIENTS, TUMORS, AND METHODS
    1. Patient Series I-IV
VHL prevalence and long-term prognosis of 110 patients with HBs of the CNS (I)
The files of the Department of Neurosurgery, Helsinki University Central Hospital
(HUCH), a unit practicing the so-called population-based responsibility service system,
revealed 110 consecutive HB patients fulfilling the following criteria: primary operation for
HB(s) of the CNS between 1953 and 1993, histologic verification of the solid part, and
HB ascertained at histological re-examination by a neuropathologist.
All available clinical data were collected to find out the occurrence of VHL
manifestations in these 110 HB patients (50 men, 60 women). The records of the
Department of Neurosurgery and all other hospitals involved were surveyed for clinical,
imaging, operative and autopsy evidence of VHL. The addresses and the death certificates
of the patients were obtained from the Population Register Center (PRC) of Finland and
Statistics Finland. A detailed inquiry on all their illnesses, hospital admissions and
operations was sent to patients before the follow-up examination. The follow-up time
started at the date of the primary operation and ended at death (49/110 patients) or on
August 31, 1998. No patient was lost to follow-up.
A detailed clinical examination to reveal signs of VHL was performed between
1991 and 1998 in 61 of the 66 live patients. This included family history for VHL, a
physical and neurological examination, ophthalmologic examination including indirect
ophthalmoscopy and Goldmann 3-mirror contact lens fundus examination, enhanced MRI
(1.0 T) of the head and upper cervical spine, and enhanced CT of the upper abdomen
(kidneys, adrenals, liver and pancreas).
VHL prevalence and long-term prognosis of vision in 36 patients with HBs of the retina
(II)
According to the hospital files altogether 36 consecutive patients with retinal
HB(s) were treated at the Department of Ophthalmology, HUCH, a unit also based on the
population responsibility service system, between January 1, 1974, and June 30, 1998, and
these 36 patients were included in the study.
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The files of the Department of Ophthalmology, and all other hospitals involved
were surveyed for clinical, imaging, operative and autopsy evidence of VHL in the 36
patients (10 men, 26 women). The addresses and the death certificates of the patients were
obtained from the PRC and Statistics Finland. The follow-up time started at the detection
of retinal HB(s) and ended at death (6/36), emigration (1/36), or on December 31, 1998.
No patient was lost to follow-up.
All living patients were invited to a multidisciplinary follow-up evaluation between
1991 and 1998. Of the 36 patients, 31 (86%) were able to attend the detailed clinical
examinations to reveal signs of VHL, including family history for VHL, neurological
examination, enhanced MRI (1.0 T) of the brain and the spinal cord, enhanced CT of the
upper abdomen (kidneys, adrenals, liver and pancreas). Complete ophthalmologic
examination included indirect ophthalmoscopy and Goldmann 3-mirror contact lens fundus
examination. In the remaining five patients (one had emigrated, three had died and one
refused to participate), all available ophthalmologic and other relevant data from other
centers were reviewed.
Gamma knife radiosurgery in 11 HBs of the CNS (III)
The database of the Gamma Knife Center at the Department of Neurosurgery,
Karolinska Hospital, Stockholm, Sweden, revealed 10 consecutive patients treated for
HB(s) of the CNS with the GK between April 11, 1978, and November 30, 1994. They
account for 0.4% of the 2796 patients treated in the same period. There were five men and
five women (median age 48 years). The native countries were Sweden (4), Germany (2),
United Kingdom (1), Belgium (1), USA (1) and Greece (1). Four of the ten patients had a
clear clinical manifestation of VHL including multiple intracranial HBs, retinal HBs,
internal organ cysts or family history. Three VHL patients had multiple intracranial HBs at
the time of RS. No linkage or mutation analyses were performed.
Eleven HBs (nine cerebellar, one mesencephalic and one suprasellar) were treated
with the GK. Six of the 11 tumors were histologically verified as HBs, five of them before
and one after RS, and four tumors occurred in VHL patients giving indirect evidence of
histology. Histological sections were not reviewed. In one tumor, the diagnosis was based
on radiological findings only. At the time of RS, six HBs were solid and five were cystic.
Pretreatment angiograms, CT or MRI scans of nine HBs were re-examined, and the
median of the largest diameters was 14 (range 6 - 43) mm. Symptoms attributable to the
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HBs intended for RS were present in five patients, and in the remaining five patients these
HBs were incidental. None of the eleven HBs had been embolized or irradiated before, but
four HBs were residuals or recurrences from previous surgery.
The first three HB patients were treated with the GK prototype Mark II, used from
1975 to 1988, and the next seven patients with the Leksell gamma knife Type B, used
since 1988. Dose planning was based on angiography in two patients, on CT in six
patients, and on MRI in two patients. The margin dose was reduced in 1990 reflecting a
general tendency to lower doses, and the six HBs before 1990 received a median of 25
(range 20 - 35) Gy while the next five HBs received a median of 10 (range 5 - 19) Gy.
All available data on the clinical course of the ten patients and their
neuroradiological studies after RS were gathered from the files of the Karolinska Hospital
and the referring physicians and hospitals. For the first patient no medical records after RS
were obtained, and the follow-up information was given by a relative. Medical records
were available for the next nine patients until death or the last follow-up date in 1994 or
1995. In eight tumors, the response until the last follow-up or subsequent surgical removal
was evaluated from the original radiological images, whereas in two HBs the response
could be assessed from the radiological reports only. The volumes (total area of the slices
x slice thickness) of the tumors and cysts were calculated using a computerized planimeter.
IFNα2a treatment in 18 HBs of the CNS and retina (IV)
Three VHL patients with 14 small, asymptomatic HBs of the CNS and three
asymptomatic retinal HBs, and one non-VHL patient with one HB of the CNS were
included in the study. A base-line work-up consisted of a physical and neurological
examination, obtaining family history for VHL, complete ophthalmologic examination
including indirect ophthalmoscopy and Goldmann 3-mirror contact lens fundus
examination and FA in patients with retinal HBs, enhanced high-resolution MRI of the
head and the spine, and enhanced CT of the kidneys, adrenals, liver and pancreas.
Recombinant human IFNα2a (Roceron-A®, Roche, Switzerland) was injected
subcutaneously (s.c.) by the patients themselves at a dose of 3x106 International Units (IU)
three times per week for 12 months. When necessary, anti-inflammatory drugs were
administered to prevent shivering and other flu-like symptoms after the injections. Side-
effects were recorded at follow-up examinations performed at few-month intervals in a
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hospital out-patient department. The blood cell counts and liver transaminases were
monitored. The WHO classification112 was used in the grading of toxicity.
The response of the HBs of the CNS and visceral cysts to treatment was judged by
comparing the sizes of the lesions (maximal diameter in mm) at three, 13, and 21-22
months after the start of the therapy. The diameters of the retinal HBs were measured from
retinal photographs and FAs.
To monitor the systemic effects of the treatment, the serum levels of hemoglobin,
VEGF and EPO were measured before the treatment and at three and nine months after
the initiation of the therapy. S-VEGF concentrations were determined as S-VEGF
immunoreactivity, using a quantitative sandwich enzyme immunoassay technique
essentially as described earlier (Quantikine R, R&D Systems, Minneapolis, MN)148. The
serum levels of EPO were measured as S-EPO immunoreactivity (Human EPO IVD, R&D
Systems, Minneapolis, MN) essentially similarly to S-VEGF measurement.
    2. Histological and proliferation analysis (Patient Series I)
The histological verification of HBs of the CNS was performed by a
neuropathologist according to the WHO classification of tumors17,87. Proliferation by
MIB-1 (Ki-67) labeling could be studied in 39 of the primary 87 HBs operated on between
1968 and 1993, and in 11 recurrences and second tumors of these patients. Briefly,
monoclonal antibody MIB-1 (IgG, Immunotech, Marseille, France) was used on
deparaffinized and rehydrated tissue sections. The sections were treated in a microwave
oven and the primary antibody was visualized with a streptavidin-biotin technique (Zymed
Laboratories, CA)146. The proliferation index (MIB-1 index) is the percentage of
immunopositive tumor cell nuclei among at least 500 neoplastic nuclei69.
     3. Finnish Cancer Registry (Patient Series I-II)
The population-based nationwide Finnish Cancer Registry (FCR) has functioned
since 1953. All hospitals, health care centers, physicians, and pathological laboratories are
requested to notify the FCR of all cancer cases (benign and malignant CNS tumors
included) that come to their attention, and the FCR also receives information of all death
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certificates with a cancer diagnosis: over 99% of the 63 722 solid tumors diagnosed in
Finland between 1985 to 1988 were recorded at the FCR166. Furthermore, everybody
living in Finland has had an 11-digit personal identification code since 1967 allowing
complete follow-up of every person for death and emigration, and also linking files
between different registries.
    4. Pedigree analysis (Patient Series I-II)
In Patient Series I, altogether 35 out of the 110 HB patients had at least some data
suggestive of VHL. Detailed pedigrees with first and second degree relatives were
constructed for them by interviewing the patients or using the files of the PRC and the
parish records. The 35 patients with their 471 relatives were linked with the files of FCR to
find VHL-related neoplasms (HB of the CNS, RCC, pancreatic carcinoma,
pheochromocytoma). In Patient Series II, detailed pedigrees including first and second
degree relatives were constructed for all 36 patients in the series. These 36 patients and
their 995 relatives were also linked with the files of FCR to find VHL-related neoplasms.
    5. Mutation analysis (Patient Series I-II)
In Patient Series I, germline mutations of the VHL gene were analyzed by direct
sequencing from peripheral blood samples of all live patients with clinically definite VHL
(4/14), suspect patients with HB and internal organ cyst(s) (11/13), and also in 25
apparently sporadic HB patients. In Patient Series II, germline mutations of the VHL gene
were studied by direct sequencing in 29 of the 36 patients. In both series, high molecular
weight DNA was extracted from peripheral blood leukocytes by the QiA Amp Blood kit
(QiAGEN Ltd., Cambridge, UK). The three exons of the VHL gene (coding region of 852
nucleotides) were sequenced, including the exon splice sites. The primers and the PCR
conditions (with slight modification) were as described elsewhere25. We also used a
reverse primer for the exon 1, SS1, 5'GCGGTAGAGGGGCTTCAGACCGTG-3'. PCR
products were purified with the QiA quick PCR purification kit (Qiagen, Hilden,
Germany), and the sequencing reactions were done using the ABI PRISM DYE
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Terminator sequencing kit (Perkin-Elmer Applied Biosystems Division, Foster City, CA);
the products were analyzed on the ABI 373 A sequencer. Both strands were sequenced.
     6. VHL criteria (Patient Series I-IV)
Diagnosis of VHL is based on mutation analysis94,161, and clinical manifestations
during long-term follow-up31,108,111,114. According to the traditional VHL
criteria31,108,111,114, also patients with multiple HBs of the CNS or retina as the only
manifestations have VHL. In our study, a patient with HB(s) of the CNS or retina was
classified as having (1) definite VHL if the patient had a germline mutation or family
history of VHL or other VHL-related neoplasms (RCC, pancreatic carcinoma,
pheochromocytoma). A patient with no family history and no other VHL-related
neoplasms had (2) suspect VHL if the patient had either (a) one HB of the CNS or retina
and visceral cysts or (b) more than one retinal HB.
    7. Statistical methods (Patient Series I-III)
Median and range were used to describe distributions, and Mann-Whitney or
Kruskal-Wallis tests to compare groups. Fisher’s exact test (2-tail) and Yates’ corrected
Chi-square test were used to assess differences in frequencies in the different patient
groups.
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RESULTS AND DISCUSSION
1. VHL prevalence and long-term prognosis of 110 patients with HBs of the CNS (I)
The prevalence of VHL in patients with HB(s) of the CNS
All available clinical data gathered during the median follow-up time of 14 (range
0.3-36) years together with a detailed clinical examination (61/110 patients), family history
(93/110 patients), detailed pedigree (35/110 patients), mutation analysis (40/110 patients)
and linkage to the files of the FCR (35 HB patients and 471 relatives) led to the distinction
of three different patient groups: (a) 14 VHL patients (13%); (b) 13 patients with a single
HB and visceral cyst(s) but no other VHL manifestations; and (c) 93 apparently sporadic
HB patients. The linkage of HB patients and their relatives to the FCR files to find out
VHL-related tumors did not disclose new VHL families.
The mutation analysis could be performed in four VHL patients, in 11 patients with
a single HB and visceral cyst(s), and in 25 patients with a single HB. We used direct
sequencing of the VHL gene which is more sensitive than SSCP (Single Strand
Conformation Polymorphism) which detects 50% of VHL mutations25,94,178. We found
a germline mutation in exon 1 in two of the four VHL patients studied (278 G to C and
293 A to G), but in none of the other 36 patients. Both mutations cause an aminoacid
missense substitution (Gly - Ala and Tyr - Cys, respectively), and are known to be
associated with pheochromocytomas26, which appeared in the family of one VHL patient.
Recent data suggest that with combined techniques (quantitative Southern blotting,
Southern blotting, FISH, and complete sequencing of the gene) virtually all mutation
carriers, also those with deletions, could be identified129,161.
The prevalence of at least 13% of VHL in this unselected and population-based
series of 110 patients operated on for HBs of the CNS appears to be an underestimation
when compared to recent studies12,61,107,117,138,140, showing prevalences of up to
40%. Our series was retrospective, spanning over four decades, and characterized by high
operative mortality in the early years. On the other hand, the follow-up time was long and
all available data were collected to detect the cases of VHL: 61 live patients were studied
clinically in detail, eight patients had clearly developed VHL, in 17 patients autopsy
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excluded VHL, and 12 patients reached the age of 65 years or more without signs of VHL.
This left 13 patients with data insufficient to rule out VHL.
Characteristics of VHL patients
Of the unrelated 14 VHL patients (five men, nine women), six (43%) had a family
history of VHL, and eight apparently had a new mutation, a proportion corresponding to
the literature104. The frequency of VHL in patients operated on for HB(s) of the CNS
was 31% (4/13) before the age of 25, 19% (9/48) between 25 and 45 years, and only 2%
(1/49) after 45 years. In 11 of the 14 VHL patients (79%), HB(s) of the CNS was the first
manifestation of the disease. Multiple HBs of the CNS were detected in 10 patients and a
single one in four, retinal HBs in eight patients (5/8 bilateral), RCC in 10 patients (6/10
bilateral), and pheochromocytoma in two patients (one bilateral), pancreatic carcinoma in
one patient, bilateral renal cysts in eight patients, and pancreatic cysts in three patients. No
liver cysts were encountered. In the 14 VHL patients, the median age at the first operation
for HB(s) of the CNS was 33 (18-50) years, significantly (p=0.005) less than the 45 (16-
79) years in the 96 non-VHL patients (45 men, 51 women) in concordance with earlier
studies118,138. The median age at the detection of retinal HB(s) was 39 (range 19-65)
years in contrast to the 25 years in VHL-based series118,170. RCC was detected in 10
VHL (67%) patients (two at autopsy) at the median age of 43 (range 26-57) years,
somewhat later than the 33 years in a recent series118, and at a median interval of 11
(range 0.1-25) years from the first operation for HB(s).
HB of the CNS
The site of the HB(s) differed between VHL and non-VHL patients: brainstem or
spinal HB(s) occurred at some stage in half of the 14 VHL patients, whereas only 5%
(5/96) and 4% (4/96) of the non-VHL patients had a single HB in either of these two
locations, in concordance with the literature53,79,107,138,140. Brainstem and spinal cord
locations contribute to the increased management morbidity of HBs in VHL.
Supratentorial HBs are rare138. In our series, two of the 14 (14%) VHL patients and three
of the 96 (3%) non-VHL patients had a supratentorial HB. Of the 110 patients, 14 died
within three months after the primary operation, mostly in the early years. During the last
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10 years, there was only one (4 %) operative death after partial removal of a brainstem HB
out of the 26 operations performed.
HB is a slowly growing tumor. There is a general impression that VHL-associated
HBs grow faster than sporadic HBs, but this is difficult to prove because no volume
growth data are available for non-VHL tumors. Time to recurrence in the original
operation area after seemingly complete removal tells something about the volume growth
rate but de novo tumors may be mistaken for recurrences in VHL patients. HB is a
microsurgically curable tumor, but the risk of late recurrences may be higher than generally
expected. Recurrence of an HB in the original operation area developed in four of the 10
VHL patients whose primary operation was considered to be radical, at two, 16, 21 and 25
years (median 19 years), and in nine of the 74 non-VHL patients at a median of 11 (range
3-35) years. The time to recurrence did not differ between VHL and non-VHL patients,
suggesting a similar growth rate of HBs in both groups, in agreement with low MIB-1
labeling indices (0.3% for 9 VHL tumors vs. 0.2% for 41 non-VHL tumors). In a previous
series of 26 HB patients operated on between 1974 and 198639, seven patients developed
a recurrence at a mean interval of seven years after total removal. There was no distinction
of VHL-related HBs. The mean MIB-1 index was 2.8%, higher than in our series, possibly
due to differences in staining and quantitation protocols. In our series, seven of the 13
patients with recurrences died of recurrence at a median of 20 (range 3-35) years after the
primary complete removal of the tumor. Late recurrences are a challenge in terms of
detection and microsurgery in elderly persons.
HB of the retina
We performed a detailed ophthalmologic examination of 60 of the 110 patients,
and another 35 patients had had ophthalmoscopy earlier during the follow-up. No
ophthalmologic data were available on 15 patients. Retinal HBs were detected in eight
patients, and only two of them had retinal HBs as their first VHL manifestation. In larger
VHL series, retinal HB is the first manifestation in about half of the patients105,118. In
our series, four VHL patients had visual disturbances, and four were asymptomatic at
detection. When a patient had HBs both in the CNS and the retina, there were always
other VHL manifestations present.
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Lesions suggestive of VHL
In 11 of the 14 VHL patients, the upper abdomen was studied by CT, US, surgery
or autopsy, and cysts were found in eight patients. None of the cysts were the sole
indication for surgical intervention. There were 13 patients with a single HB and
asymptomatic cyst(s) of internal organs. The median age of 56 years at the first HB
operation, the lack of other VHL-associated manifestations, negative family history, and
no germline mutations of the VHL gene (11 patients studied) together suggest that the
internal organ cyst(s) in these 13 patients were incidental findings. The cyst(s) occurred in
the kidney(s) in 10 patients (three bilateral), in the liver in four patients, in the pancreas in
two patients, and in the spleen in one patient. In our series, the abdominal organs of 60
patients, regarded to be free of VHL, were imaged by CT (54 patients) or US (six
patients), and incidental cysts were found in 17% (10/60) in the kidneys, 7% in the liver
(4/60), and 3% (2/60) in the pancreas. Visceral cysts in patients with a single HB of the
CNS may suggest VHL. In our series, however, 13 (14%) HB patients who were
considered as free of VHL had visceral cysts. Characteristically, they had fewer cysts per
organ and patient than did the VHL patients. The occurrence of non-VHL cysts in our
series corresponds to that of the general population18,74,95,168.
The lesions detected in VHL may also occur incidentally in otherwise healthy
subjects, but typically at an older age than in VHL patients118,138. Multiple HBs of the
CNS are considered as a classical sign of VHL. In our series, one non-VHL patient (1%)
had two HB nodules in the same cyst wall at the primary removal. A negative family
history and no germline mutation together with the lack of other VHL manifestations
during the long follow-up suggest that this patient did not have VHL. Multiple HBs may
still represent mosaicism or segmental VHL, the negative family history explained by a
mosaicistic or no VHL gene defect in the germ cells. Neurofibromatosis type 2 (NF2),
another dominantly inherited syndrome with a defective NF2 tumor suppressive gene
predisposes to multiple schwannomas and meningiomas, but the defective NF2 gene may
also cause sporadic schwannomas and meningiomas52,78,102,152,153. In the
schwannoma population, 95% of the patients have single and obviously sporadic tumors,
2% have multiple but without classical NF2, and in 3% the tumors are related to NF23.
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Long-term survival of patients with HB(s) of the CNS
In our series, 12 of the 14 VHL patients survived at least two years after the
primary HB operation. The median follow-up time for these 12 patients was 16 (range 4-
26) years, and during the follow-up nine of them died at a median age of 47 (range 26-66)
years. All died of the disease, five of RCC at a median of 49 (range 26-66) years, three of
HB(s) at a median age of 47 (range 46-51) years, and one of pancreatic carcinoma at 45
years. 70 of the 96 non-VHL patients survived more than two years after the primary
radical HB removal. During the median follow-up time of 16 (range 2-36) years, 18
patients died at the median age of 65 (range 51-81) years. There were six deaths due to
recurrence of the HB in the original operation area after a median of 15 (range 3-35) years
at the median age of 66 (range 55-81) years, and 12 non-related deaths at the median of 65
(range 51-77) years.
The average life-expectancy of VHL patients is 40 to 50 years115. At present RCC
is the leading cause of death of VHL patients105, and it was also a major cause of
mortality in our series. In a recent series of 65 VHL patients with RCC treated with radical
nephrectomy or nephron-sparing surgery, the RCC specific survival rate at five and 10
years was 95 and 77%, respectively, but 23% of the patients developed end-stage renal
failure157. Renal transplantation is an option to treat anephric VHL patients. The results
from a series of 28 patients suggested that immunosuppression would not enhance the
growth of existing tumors65. Further studies with long follow-up are needed to show
whether prolonged immunosuppression increases the risk of second malignancies in VHL
patients with renal transplants132. These aspects are crucial when deciding whether
prophylactic bilateral nephrectomy with renal transplantation is offered as a life-saving
treatment for VHL patients. Another possibility would be to develop a specific drug
therapy against HBs and RCCs, e.g. relating to angiogenesis in both tumors.
Early detection of VHL lesions
All patients with HB(s) of the CNS should be screened for VHL by MRI of the
brain and spinal cord, ophthalmoscopy, abdominal CT or MRI, and by obtaining the family
history and performing VHL germline mutation analysis61. The children of a patient with a
VHL gene defect have a 50% risk of getting the disease, and they should be offered the
possibility of predictive germline mutation testing to avoid laborious and expensive long-
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term clinical screening. Furthermore, it was recently shown that patients with mutations
causing truncation or deletion of the VHL protein developed more often multiple HBs of
the CNS and had more often multiple operations than patients with mutations predicted to
produce a full length VHL protein61. This suggests that truncating mutations induce a
more severe disease and thereby might influence the clinical management61. Early
detection of incidental HB(s) of the CNS may be more favorable at least in terms of
radiosurgery23,125. When retinal HBs are small and asymptomatic they are easier to treat
with laser or cryocoagulation, and the prognosis of vision is better174. Early detection
probably ensures also a better prognosis of RCC65,120,157.
2. VHL prevalence and long-term prognosis of vision in 36 patients with HBs of the
retina (II)
Distinction of VHL patients among patients with retinal HB(s)
All previous clinical data, and the present data obtained by a detailed clinical and
radiological examination (31/36 patients), pedigree analysis (36/36 patients), germline
mutation analysis (29/36 patients), and linkage of the 36 patients and their 995 first and
second degree relatives (a median of 28 relatives per patient) to the files of the FCR led to
the distinction of three patient groups: 1) 11 definite VHL patients (30%); 2) 10 suspect
VHL patients (28%) with multiple retinal HBs or with a single retinal HB and visceral
cysts but no other VHL-related neoplasms and no family history; and 3) 15 non-VHL
patients (42%) with a single retinal HB. The linkage to the FCR files to find VHL-related
tumors did not disclose any VHL patients or families not known before. The germline
mutation analysis by direct sequencing was possible in eight of the 11 clinically definite
VHL patients and disclosed a mutation in six (75%): three in exon 1 (277 G to C causing
amino-acid missense substitution Arg to Pro; 278 G to C causing substitution Gly to Ala;
and 293 A to G causing substitution Tyr to Cys) and three (two patients from the same
family) in exon 3 (all three 501 C to G causing substitution Pro to Arg). The sequencing of
the VHL gene was performed in nine of the 10 suspect VHL patients and in 12 of the 15
patients regarded clinically as free of VHL, and did not reveal any mutations. The missense
mutations found in our series are known to be associated with pheochromocytomas25,
which were present in one VHL patient and in the family of another VHL patient.
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In our series, there was a female predominance (2.6:1) among 36 patients with
retinal HBs for unknown reasons, in VHL (1.8:1), suspect VHL (all women) and non-
VHL cases (1.5:1). Similarly, Webster et al.169 found a female predominance (2.4:1) in
their 17 non-VHL patients, and there was also an excess of women among the VHL
(1.4:1) and non-VHL (2:1) patients, with uncertain VHL exclusion, collected from the
literature by Chang et al.22. In HBs of the CNS, there is only a slight female predominance
according to a literature review by Resche et al.138 in concordance to our series of 110
patients (1.2:1).
Definite VHL patients
In our series, in the 11 definite VHL patients (four men, seven women), HBs of the
retina were detected at a median age of 27 (range 11-65) years in concordance with the
literature118. Eight VHL patients (73%) had familial disease (seven unrelated pedigrees),
and three patients apparently had a new mutation. At detection, three patients (27%) had
one unilateral retinal HB, six (55%) had bilateral HBs, and one had two HBs in one eye.
During a median follow-up time of 12 (range 1.5-30) years, six patients developed new
retinal HBs outside the already treated areas. Eventually, 21 eyes became affected, and the
number of HBs varied from one to seven per eye. As other manifestations of VHL, HBs of
the CNS were detected in nine of the 11 VHL patients (82%) at the median age of 32
(range 18-59) years, corresponding to the literature118, RCC in seven at the median age
of 40 (range 28-57) years, somewhat later than in recent series118, and
pheochromocytoma in one patient. Cysts of the internal organs were detected in nine
patients (82%).
Suspect VHL patients
In general, the presence of more than one retinal HB is suggestive of
VHL138,169,170. At the end of the median follow-up time of five years (range 0.2-21
years) five female patients had either bilateral HBs or more than one unilateral HB without
other VHL-related neoplasms. At detection, two of the patients had bilateral HBs, one had
two and one had four unilateral HBs. Two patients (one with bilateral HBs at detection)
developed new lesions outside the already treated areas. The median age of 40 (range 14-
45) years at primary detection, negative family history, the lack of other VHL
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manifestations (one patient with a single renal cyst), and no germline mutations detected
(4/5 patients studied) are findings resembling those in non-VHL patients. Only one patient
has died of a non-related cause at the age of 35 years. These patients may thus have a mild
form of VHL. Our detection method, i.e. direct sequencing, picks up 60-70% of VHL
gene mutations, but misses large deletions25,26,161,178. These multiple HBs may also
represent germline mosaicism or a segmental cell population with the VHL gene defect, or
although unlikely, a local spread of the same tumor. In any case, this patient group with a
favorable overall prognosis should be followed up to define the natural history of this
condition. Thus, multiple HBs of the retina as well as HBs of the CNS without other VHL
manifestations may represent an entity similar to schwannomatosis but without
NF250,78,102,153.
Another five female patients with a single retinal HB, detected at the median age of
37 (range 25-61) years, had visceral cysts. However, a negative family history, the lack of
other VHL manifestations, and no germline mutations detected (all patients studied)
suggest that the retinal HB(s) in these five patients were not related to VHL. The
occurrence of visceral cysts in patients with retinal HBs (in 10% in the kidneys, and in
15% in the liver) corresponds to that of the incidental cysts in the general
population18,74,95,168. Furthermore, the number of cysts per organ and per patient was
less than in the definite VHL patients. Therefore, the five patients most probably represent
non-VHL patients with sporadic visceral cysts.
Non-VHL patients
Fifteen of the 36 patients (nine women, six men) had only a single HB of the retina
detected at the median age of 40 (range 17-58) years, later than the 28 (range 3-52) years
reported in a recent series of 17 non-VHL patients169. No de novo HBs appeared during
the median follow-up of two (range 0.2-17) years. The lack of other VHL manifestations,
negative family history, and no germline mutations of the VHL gene (12/15 patients
studied) suggest that the retinal HB was not VHL-related.
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VHL prevalence in retinal HBs
The prevalence of VHL in our series of 36 consecutive patients with retinal HB(s)
varies between 30 and 58%, which is much higher than in our series of 110 patients with
HBs of the CNS. Earlier, without the possibility of germline mutation analysis and modern
imaging to exclude VHL, it was postulated that retinal HB(s) are always, or in most cases,
related to VHL114,138. Recently, Webster et al.169 were able to identify 17 non-VHL
patients with retinal HBs collected from several ophthalmologic and genetic centers in the
UK, using MR imaging and mutation analysis. Our series is the first consecutive series of
patients with retinal HB(s) treated at a single center with population responsibility. Our
study, which excluded VHL with meticulous multidisciplinarity, should reflect the true risk
of VHL, patient characteristics and outcome of vision in patients with retinal HB(s).
Long-term prognosis of vision in patients with retinal HB(s)
Retinal HBs were detected at a younger age in VHL than in non-VHL patients, at
least partly due to awareness of the disease in the family and earlier screening, analogous
to HBs of the CNS118,138 and tumors in other familial cancer syndromes52. However,
Webster et al.169,170 found no age difference. Retinal HBs were incidental findings in
55% of our definite VHL patients, corresponding to previous studies108, and in 40% of
the non-VHL patients, less than the 63% reported by Webster et al.169. In our series, the
appearance of retinal HBs did not differ between definite VHL, suspect VHL and non-
VHL patients.
Six of the 11 definite VHL patients (55%) (median age of 31, range 23-65 years),
two of the 10 suspect VHL patients (1/5 and 1/5, respectively) and six of the 15 non-VHL
patients (40%) were asymptomatic at detection of retinal HB(s). One patient from each of
the three categories had incipient HBs without draining vessels, all the others had typical
mature HBs of varying sizes with dilated and tortuous draining vessels. One suspect VHL
patient with visceral cysts had a single juxtapapillary HB.
Five VHL patients had visual impairment with one blind eye (median age of 27,
range 11-57 years). During the follow-up, five more eyes in VHL patients lost light
perception. Two VHL patients became totally blind due to retinal detachment and/or
neovascular glaucoma. At detection, one eye in a suspect VHL patient had lost light
perception due to vitreous hemorrhage, total retinal detachment and neovascular glaucoma
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caused by a large HB. At the end of follow-up the patient was legally blind (vision
<20/400 in the better eye). In two more eyes, vision remained impaired (<20/60) in spite of
vitreoretinal surgery. None of the non-VHL patients, on the contrary, had visual acuity
<20/60 in the affected eye.
Thus, in our series, the prognosis of vision in eyes with retinal HB(s) was more
favorable in non-VHL than in definite VHL patients, whereas the outcome witnessed by
Webster et al.169,170 was equal in both groups. In general, the suspect VHL patients in
our series had a prognosis of vision resembling that of the non-VHL patients. However, in
one patient with bilateral HBs, and in another with unilateral multiple HBs, visual outcome
resembled that of the definite VHL patients. No enucleations were performed in our 15
non-VHL patients, whereas two of the 17 affected non-VHL eyes were removed in the
series of Webster et al. 169. In our 11 definite VHL patients, all but one had bilateral
disease, and at the end of the follow-up altogether six eyes (29 %) had lost light
perception, one of them enucleated, and two patients were totally blind, a finding
emphasizing the importance of ophthalmologic screening and early treatment of retinal
HBs in VHL patients174.
Early detection of VHL lesions
The average life-expectancy of VHL patients is 40 to 50 years115. It was 50 years
in our series, and all patients died due to VHL (two of RCC, and two of HBs of the CNS).
Therefore, all patients with retinal HB(s) should be screened for VHL by MRI of the head
and spine, upper abdominal CT or MRI; the family history should be obtained, and
germline mutation analysis performed. Patients with a single retinal HB but no other VHL
manifestations, negative family history and no germline mutations should remain in
ophthalmologic control. Genetic counseling should be offered to all VHL patients, and
annual life-long follow-up should be arranged conjointly by an ophthalmologist, a
neurosurgeon, and a urologist. Retinal screening of children at risk should start as soon as
co-operation permits the detection of even incipient HBs.
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3. Gamma knife radiosurgery in 11 HBs of the CNS (III)
Response of the solid part
In our series, CT or MRI scans were available of 10 of the 11 HBs at four to 68
(median 26) months after RS. The solid part shrunk in six HBs in a median of 30 months,
while four HBs were found unchanged in a median of 14 months. The solid part of three
HBs were operated on after RS. In one patient the tumor was resected at 17 months
although it had reduced in size. In another patient the tumor was unchanged at 31 months,
but it was removed at 51 months along with the evacuation of a de novo cyst. In one
patient the tumor, unchanged at six months, was removed at 38 months because it
maintained a cyst, but no imaging data was available on the size of the tumor at that time.
It was not possible to determine whether RS had affected vascularity or resectability of
these three HBs, and no histological specimens were available.
Single sporadic HBs rarely come to RS, because seemingly complete microsurgical
removal of the solid part is almost always curative and ceases cyst formation. Chandler and
Friedman21 treated a non-cystic HB (10 x 15 mm) in the floor of the fourth ventricle with
LINAC radiosurgery because the patient had not tolerated brain stem manipulation during
open surgery. Two years after a margin dose of 15 Gy (90% isodose line, 16-mm
collimator) her status was still normal and the tumor size had remained unchanged. We
obtained reliable follow-up data on five sporadic cerebellar HBs. No symptoms suggesting
radiation injury developed in a median follow-up time of 42 (range 21-122) months. The
median tumor diameter was 14 (range 6-43) mm and the median margin dose was 15
(range 5-25) Gy. Radiological studies at a median of 19 (range 6-33) months showed that
the solid part had not increased in any of the five HBs. However, the two largest tumors
with diameters of 31 mm and 43 mm had been operated on at 17 and 38 months,
respectively. Together these six cases indicate that RS is a well tolerated means to shrink
or stabilize small and medium-sized single sporadic HBs, but the tumors so treated must be
followed up for a long time. It remains to been seen how RS affects possible later resection
of the solid part, the tumor vascularity and adherence to the adjacent brain.
VHL patients have an inherited tendency to develop multiple cerebellar, cerebral
and spinal HBs. Microsurgery is not an ideal method to control them in the long run,
because repeated exposures cause cumulative neuronal damage. Page et al.130 treated
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nine solid and two cystic posterior fossa HBs in four VHL patients using LINAC
radiosurgery to achieve a margin dose of 30 to 35 Gy. The tumors were rather small with a
median diameter of 10 (range 1.5-20) mm. Chang et al.23 treated 29 HBs in 13 VHL
patients using LINAC radiosurgery. The radiation dose to the tumor periphery averaged
23 (range 18-40) Gy. In our series, four solid HBs and one cystic HB in four patients were
treated with a median margin dose of 25 (range 8 to 35) Gy. The median diameter of the
solid part was 12 (range 10 to 24) mm. Combined follow-up imaging data of these 45
tumors suggest that RS is able to shrink or stabilize the solid part of HB associated with
VHL.
Response of the adjacent cyst
The solid part of an HB has a tendency to create and maintain an adjoining cyst by
a mechanism which is thus far unknown. Removal of the solid part is an adequate
treatment also for the cyst, which indicates that the cyst is not maintained by an actively
secreting capsule. RS is therefore targeted at the solid part of HB, and it is not feasible to
irradiate the periphery of the cyst. In our series, five HBs had an associated cyst at the time
of RS. Two of these five cysts required evacuation at six months, and one at 31 months
after RS. Six HBs had no adjoining cyst at the time of RS, but during the follow-up one of
them developed a cyst necessitating evacuation 51 months after RS. The combined follow-
up data of 90 HBs in 50 patients21,23,130,131, including the present series, confirm that
RS of the solid part may not prevent cyst formation. The adjoining cyst may enlarge and
necessitate evacuation despite regression of the solid part, and RS of a solitary HB does
not necessarily prevent formation of a de novo cyst later. The mechanism by which RS
affects the endothelial cells and parenchymal cells of HB is unknown. Because the
response is slow, the cyst forming secretion from HB tissue may continue for a
considerable time. Consequently, removal of the solid part may become necessary if it
maintains a cyst in the long run.
Morbidity and tumor margin dose
In our series, no acute adverse effects attributable to the gamma knife procedure
were registered. Page et al.130 used high tumor margin doses (30-35 Gy) and two of the
four patients suffered transient nausea and vomiting immediately after treatment.
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Overlapping fields may occur in VHL patients because of multiple HBs, and this increases
the risk of delayed radiation injury. In our series, one patient had two cerebellar HBs
treated in the same session, each receiving a margin dose of 25 Gy in one shot with a 14-
mm collimator. At six months she developed cerebellar edema requiring a shunt and
prolonged corticosteroid treatment. The patient with a suprasellar HB received a margin
dose of only 8 Gy in three shots with an 18-mm collimator, but at 22 months she became
confused and had severe hyponatremia due to inappropriate secretion of antidiuretic
hormone (SIADH); her tumor, however, was found regressed. On the other hand, a
margin dose of 20 Gy in one shot with an 8-mm collimator in an eloquent area, the
midbrain, did not cause side-effects during a 13-month follow-up. In the series of Chang et
al.23 the radiation dose to the tumor periphery averaged 23 (range 18-40) Gy. Three out
of 13 patients (23%) developed radiation necrosis during the mean follow-up of 43
months, but two of the three patients remained asymptomatic. Patrice et al.131 used a
lower median dose of 16 (range 12-20) Gy but three out of 22 patients required
corticosteroids after RS. One patient was treated with corticosteroids eight months after
RS for symptomatic mass effect prior to undergoing reoperation131. Our last five cases
with a reduced dosage suggest that the solid part was controlled by a margin dose of 10-
15 Gy, but as stated above, cyst formation is usually not prevented.
4. IFNα2a treatment in 18 HBs of the CNS and retina
Patients and HBs
At the beginning of the IFNα2a treatment, the three VHL patients had altogether
14 small untreated HBs of the CNS, two previously treated retinal HBs, and one untreated
retinal HB. Two VHL patients had altogether 16 renal and two pancreatic cysts, but the
third had none. The single non-VHL patient had a slowly growing HB remnant in the
jugular foramen. All patients were asymptomatic in relation to these tumors. After the 12-
month IFN therapy the patients were followed up for a further 9 to 10 months.
Overall response
During the 12-month IFN therapy, two of the 15 HBs of the CNS diminished
slightly (13%), nine remained unchanged (60%) and four enlarged (27%). During the
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subsequent nine-month follow-up, four tumors decreased slightly, six remained unchanged,
and five increased slightly in diameter. These HBs were small, and some of the changes
(+1mm) may be due to measurement errors from the MRI scans. On the other hand, small
but real changes in diameter would cause considerable volume changes. HBs of the retina
were easier to monitor, being accessible to direct visual observation of appearance and
size. Two of the three HBs of the retina slightly decreased during the treatment but one of
them increased again after the therapy, suggesting that IFNα2a diminished only their blood
flow. No de novo HBs of the CNS or retina appeared during the IFN therapy, but one new
lesion was detected nine months after discontinuation of the therapy. The treatment did not
prevent visceral cysts from enlarging and fusing. Two VHL patients had altogether eight
HBs in the spinal cord, but they did not develop marked peritumoral edema or medullary
symptoms during IFNα2a treatment. No unusual toxicity was observed, and the mild
adverse effects observed did not necessitate the reduction of the IFN dosage or
discontinuation of the treatment.
VEGF plays a role in VHL, promoting angiogenesis of HBs of the CNS and
retina64. S-VEGF levels are increased in patients with disseminated cancer147, but there
are no published data on the effect of IFNα on S-VEGF in cancer patients. In our three
VHL patients, however, there was no obvious association between the S-VEGF levels, the
number of HBs, and the effect of IFN therapy, but the number of patients is too small for
definitive conclusions. The patients did not have polycytemia and their S-EPO levels were
within normal range and remained so during the therapy. The impact of VEGF46,47 in
retinal pathology is thought to be mediated by the increasing mitogenic activity of
endothelial cells and the permeability of the vascular wall1. Furthermore, in animal studies
VEGF has associated with increased blood flow in the retina33, considered important in
the pathogenesis of early diabetic retinopathy33. Thus, IFNα2a may have, by
counteracting VEGF, decreased blood flow in HBs as suggested by shrinkage of the two
retinal HBs. Another VEGF antagonist, PKC β inhibitor, has been shown to decrease
retinal blood flow in diabetic rats77.
Dosage of IFN
The dosage of IFNα in our phase II study was rather low (9x106 IU/week for 12
months). The effect on HBs could be more pronounced with a higher or denser dosage
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such as 3x106 IU/m2/day for up to 13 months used successfully to shrink large
hemangiomas in children51. However, higher IFN doses are often poorly tolerated in long-
term use, which is necessary in treating slowly growing tumors. Furthermore, there was no
statistically significant correlation between dose intensity and the response rate in a review
of 525 RCC patients treated with IFNα71. In HBs of the CNS, it is difficult to estimate the
treatment effect, because the growth is slow39,124 and unpredictable. In VHL patients,
some tumors grow while others remain dormant. Spontaneous regression of retinal HBs
has been reported172, but usually these lesions grow, and eventually cause loss of vision if
left untreated174. If IFNα2a treatment prevents some HBs of the CNS and retina from
growing, the problem will be how to identify the potential responders. Because of the life-
long tendency of VHL patients to develop HBs, IFN therapy should be long-lasting and
continue for several years, possibly intermittently, to reduce adverse effects.
Future trends
More potent antiangiogenic drugs such as angiostatin and endostatin derivates may
offer means to prevent the appearance of new lesions or to shrink or stabilize established
ones. These drugs may be successfully combined with radiotherapy, chemotherapy or
immunotherapy.
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CONCLUSIONS
I. The frequency of VHL in 110 consecutive patients operated on for HB(s) of the CNS
was 31% before the age of 25 years, 19% between 25 and 45 years, and only 2%
thereafter. In the 14 VHL patients (13%), HB(s) of the CNS were detected at the median
age of 33 years, followed by retinal HBs at 39 years, and RCC at 43 years. Half of the
VHL patients had spinal and/or brain stem HBs at some stage in comparison to only 4-5%
of non-VHL patients. Internal organ cysts in HB patients did not necessarily indicate VHL.
The growth rates of non-VHL and VHL-related HBs were similar, as indicated by the
median time to recurrence and the MIB-indices. The median life-span of VHL patients was
46 years, with RCC and HBs as equal causes of death.
II. About one third to one half of the 36 consecutive patients with retinal HB(s) had VHL.
Internal organ cysts in patients with retinal HBs did not necessarily indicate VHL. The
appearance of retinal HB(s) did not differ between VHL and non-VHL patients. The
outcome of vision was less favorable in VHL patients. Women predominate (2.6:1) in
patients with retinal HB(s).
III. A solitary small or medium-sized HB usually shrank or stopped growing after
radiosurgery, and a margin dose of 10 to 15 Gy was sufficient. The adjoining cyst often did
not respond to the radiosurgery of the solid part, but required later evacuation, even
repeatedly. It is mandatory to follow-up radiosurgically treated HBs regularly by CT or
preferably MRI.
IV. No de novo HBs were detected during the 12-month IFNα2a therapy at a dose of
3x106 IU s.c. three times per week, but one appeared nine months after discontinuation of
the treatment. HBs of the CNS did not markedly decrease in size during the treatment, but
the dosage used may be insufficient. IFNα2a may decrease blood flow in HBs as suggested
by shrinkage of two retinal HBs, but the therapy did not prevent visceral cysts from
growing. The treatment was well tolerated.
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SUMMARY
Von Hippel-Lindau disease (VHL) is a rare dominantly inherited cancer syndrome
predisposing to multiple hemangioblastomas (HB) of the CNS and retina, renal cell
carcinomas (RCC), pancreatic carcinoma, pheochromocytomas, and visceral cysts. VHL
usually reduces life to 40-50 years, with RCC and HBs of the CNS as the main causes of
death. The HB is a highly vascular, benign and well-circumscribed, slowly growing solid or
cystic neoplasm of the CNS and retina. In HBs of the CNS, microsurgery is the treatment
of choice aided, if necessary, by preoperative embolization to reduce intraoperative
bleeding. Radiosurgery offers a non-invasive means to treat HBs in eloquent brain areas.
There are sporadic retinal HBs without VHL, but their prevalence has remained undefined.
There is increased morbidity related to repeated microsurgery and radiosurgery of HBs of
the CNS, as well as coagulation of retinal HBs. Therefore, it is justifiable to seek other
approaches to treat multiple HBs. Antiangiogenic tumor therapy is targeted to small foci of
migrating and proliferating endothelial cells in capillaries at sites of angiogenesis, in an
attempt to inhibit tumor growth. Interferon-alpha (IFNα) is a well-tolerated drug with
immunomodulatory, antiproliferative and antiangiogenic activities.
Long-term follow-up data on patients with HBs of the CNS and/or retina, treated
with population responsibility and distinction of VHL, have remained scarce. The effect of
radiosurgery in HBs of the CNS has remained undetermined. There are no published data
on the effect of IFNα therapy in HBs of the CNS and retina. The aims of this thesis were
to study the VHL prevalence and long-term prognosis of 110 patients with HBs of the
CNS and 36 with HBs of the retina, the results of gamma knife radiosurgery in 11 HBs of
the CNS, and the impact of 12-month IFNα2a therapy in 18 HBs of the CNS and retina.
The frequency of VHL in 110 consecutive patients operated on for HB(s) of the
CNS was 31% before the age of 25 years, 19% between 25 and 45 years, and only 2%
thereafter. In the 14 VHL patients (13%), HB(s) of the CNS were detected at the median
age of 33 years, followed by retinal HBs at 39 years, and RCC at 43 years. Half of the
VHL patients had spinal and/or brain stem HBs at some stage in comparison to only 4-5%
of non-VHL patients. Internal organ cysts in HB patients did not necessarily indicate VHL.
The growth rates of non-VHL and VHL-related HBs were similar, as indicated by the
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median time to recurrence and the MIB-indices. The median life-span of VHL patients was
46 years, with RCC and HBs as equal causes of death.
About one third to one half of the 36 consecutive patients with retinal HB(s) had
VHL. Internal organ cysts in patients with retinal HBs did not necessarily indicate VHL.
The appearance of retinal HB(s) did not differ between VHL and non-VHL patients. The
outcome of vision was less favorable in VHL patients. Women predominate (2.6:1) in
patients with retinal HB(s).
A solitary small or medium-sized HB usually shrank or stopped growing after
radiosurgery, and a margin dose of 10 to 15 Gy was sufficient. The adjoining cyst often did
not respond to the radiosurgery of the solid part, but required later evacuation, even
repeatedly. It is mandatory to follow-up radiosurgically treated HBs regularly by CT or
preferably MRI.
No de novo HBs were detected during the 12-month IFNα2a therapy at a dose of
3x106 IU s.c. three times per week, but one appeared nine months after discontinuation of
the treatment. HBs of the CNS did not markedly decrease in size during the treatment, but
the dosage used may be insufficient. IFNα2a may decrease blood flow in HBs as suggested
by shrinkage of two retinal HBs, but the therapy did not prevent visceral cysts from
growing. The treatment was well tolerated.
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FIGURES OF VHL LESIONS
1. HBs of the CNS
Figure 1
MRI scan of two small solid cerebellar HBs (arrows) in a 52-year-old VHL patient.
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Figure 2
MRI scan of a typical cystic cerebellar HB in a 39-year-old non-VHL patient.
Figure 3
Two solid brain stem HBs and a cystic HB in the cervical spine in a 32-year-old VHL
patient.
Figure 4
An HB in cervical spine in a 21-year-old VHL patient: MRI with contrast (a),
superselective angiography before (b) and after (c) preoperative embolization.
Figure 5
Two small spinal HBs in the thoracic region (a and b) in the same patient as in Figure 4,
three years later.
Figure 6
A large solid recurrent HB 11 years after the primary total removal in a 66-year-old non-
VHL patient.
2.  RCC and cysts
Figure 7
Abdominal CT scan of a 64-year-old VHL patient with the right kidney removed because
of RCC. The left kidney presents with RCC (a) and cysts (b).
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3. HBs of the retina
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Figure 8
A typical mature HB with a draining arteriole and venule in a 40-year-old non-VHL
patient: ophthalmoscopic view (a), and FA (b) before treatment; ophthalmoscopic view (c)
and FA (d) at two months after cryocoagulation, showing narrowing of the feeders.
Ophthalmoscopic view (e) at six months, showing shrinkage of the HB.
Figure 9
A large HB with draining vessels and lipid exudates in a 65-year-old VHL patient.
Figure 10
A juxtapapillary HB in a 25-year-old suspect VHL patient.
Figure 11
Local exudative and tractional retinal detachment caused by an HB in a 26-year-old non-
VHL patient.
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